Cancer stem cells (CSCs) have been identified in solid tumors and cancer cell lines. In this study, we isolated a series of cancer cell clones, which were heterogeneous in growth rate, cell cycle distribution and expression profile of genes and proteins, from ovarian tumor specimens of a patient and identified a sub-population enriched for ovarian CSCs defined by CD24 phenotype. Experiments in vitro demonstrated CD24
Introduction
In spite of advances in the treatment of ovarian carcinoma, it remains the leading cause of death among gynecologic neoplasms because the present therapies are limited by the emergence of chemotherapy-resistant cancer cells following the high initial-response rate (Cannistra, 2004; Naora and Montell, 2005) . Understanding the biological mechanisms mediating drug resistance may lead to new therapeutic strategies.
Recently, a cancer stem cell (CSC) hypothesis has proposed that heterogeneous tumors contain a small fraction of stem-like cancer cells with sufficiently unique properties that would allow them to survive chemotherapy and retain their tumor-initiating potential (Pardal et al., 2003; Wicha et al., 2006; Seigel et al., 2007) . These cells are named 'CSCs' because they possess properties of keeping quiescent, self-renewal and differentiation like normal stem cells. CSCs have been discovered in a large series of tumors including breast (Al-Hajj et al., 2003) , prostate (Collins et al., 2005) , pancreas (Li et al., 2007) and melanoma tumors (Monzani et al., 2007) after they were first identified in acute myeloid leukemia as possessing the cell surface antigen phenotype CD34 þ
CD38
À (Bonnet and Dick, 1997) . A significant effort is underway to identify both CSC-specific markers and the tumorigenic potential of these cells.
The existence of CSCs in ovarian cancer was first proven in multilayered spheroid cells isolated from patient ascites (Bapat et al., 2005) and subsequently verified in a mouse model using side population phenotype (Szotek et al., 2006) . Until now, CD133 (Ferrandina et al., 2008; Baba et al., 2009) , CD44/ CD117 (Zhang et al., 2008) and CD44/MyD88 (Ahn et al., 2008) ) have been used to identify ovarian CSCs. CD24, a cell surface molecule, appears to be highly expressed in a large variety of human cancers. Recent studies have suggested that CD24 might be a marker for CSCs with specific regards to the breast (Al-Hajj et al., 2003) and the pancreas (Li et al., 2007) . It should be noted that it is the absence of CD24, combining the presence of CD44 and EpCAM, that associates with breast cancer stem cells, whereas Li et al. (2007) suggested that CD44 þ CD24 þ EpCAM þ pancreatic cancer cells possessed stem cell properties. This two-edged role of CD24 in the identification of CSC attracts our more interest in the following research.
In this investigation, we isolated cancer cells from human ovarian tumor specimens and defined the heterogeneous characteristics of these cell clones and identified the potential ovarian CSCs. We revealed that a subset of CD24 þ cells in ovarian cancer possess CSCs properties of relative quiescence, self-renewal and differentiation, chemoresistance and tumorigenicity in nude mice. We also undertook investigation of the possible gene regulations of CD24. We believe this is the first time to isolate CSCs by virtue of CD24 phenotype from human ovarian cancer cells. This identification of ovarian CSCs may provide new therapeutic approaches to treat ovarian cancer.
Results

Clone derivation with different characteristics
The present culture system gave rise to 20 clones designated C2, C3, C4, C4.2, C5, C5.2, C6, C6.2, C7, C7.2, C8, C9, C10, C11, C12, C13, C13.2, C14, C15 and C20. All these clones could be successfully subcultured. Subsequent experiments were carried out on these cells cultured for 5-15 passages. Based on the hierarchy model of tumor and previous progenitor cell origin theory (Stupp and Hegi, 2007) , we postulated that these primary cancer clones were heterogeneous and CSCs, if they exist, were possibly found in certain clones.
Although no obvious variation was observed in morphology under optical microscope in these clones, growth rate ( Figure 1a ) and cell cycle distribution ( Figure 1b and Supplementary Figure S1 ) were significantly different. Subsequently, we investigated the expression of numerous 'stemness' genes, including ABCG2, CD133, CD24, CD34, CD44, CD117/c-kit, EpCAM, E-cadherin, b-catenin, SMO, Bmi-1, Nestin, Notch1, Notch4, Oct3/4, Oct4 and CK18. We found that mRNA levels of all these genes were highly expressed in all cell clones except that CD24, CD117, CD133 and E-cadherin showed a certain degree of variation between individual cell clones. The expression range of CD24, CD133 and CD117 was from total absence to high-level. E-cadherin, required in the initial invasion stage for ovarian cancer, was also found to be expressed at a lower degree in three clones than in others ( Figure 1c) .
We further detected protein levels of CD24, CD117 and CD133 by flow cytometry based on their differential mRNA levels and applications in identifying CSCs in a variety of cancers. Among the clones, 0.4-69.2% of human ovarian cancer cells expressed CD24, 0.1-1.0% expressed CD117, and 1.2-53.2% expressed CD133 (Figure 1d ), and these three surface markers were also co-expressed in small fractions of the total population. Several representative examples of single and double marker-sorted cells from a selected clone are shown (Figure 1e ).
Growth properties of purified CD24
þ and CD24 À cells in vitro Subsequently, we picked out CD24 from all potential stem cell markers and hypothesized that it was another surface marker to identify ovarian CSCs. It is accepted that remaining quiescent is one of the characteristics of stem cells. To investigate which population was more quiescent between CD24 þ and CD24 À cells, cell proliferation assay was carried out. Growth curves of sorted cells indicated that CD24
þ cells proliferated at a significantly lower rate than CD24 À cells within 1 week after sorting (Po0.05, Figure 2a) .
To explore the capacity of sorted cells for self-renewal and differentiation, highly purified CD24 þ and CD24 À cells were separately cultured in vitro for 2 weeks, and then the expression of CD24 in each population was detected by flow cytometry. We found that the proportion of CD24 þ cells dramatically declined time dependently in purified CD24
þ population, and they returned to almost presorting levels; whereas CD24
À tumor population was maintained in CD24 À cells (Figure 2b ), which indicate CD24 þ tumor cells arose only from CD24 þ population and that CD24
À cell gave rise exclusively to CD24 À progeny. Cisplatin is an important drug in the treatment of ovarian cancer, but one of its major limitations is that the initial response is always followed by the acquisition of drug resistance (Song et al., 2007) . In light of the view that cancer-initiating cells have a crucial role in the development of drug-resistance (Zhang et al., 2008) Cell cycle control is one of the important aspects in CSC biology and deregulated cell cycle control is one of the fundamentally intrinsic steps leading to CSC-derived tumorigenesis (Cheng, 2004) . To determine whether differences in proliferation, differentiation and chemoresistance observed between CD24 þ and CD24 À cells isolated from ovarian cancer were due to differences in the cell cycle distribution, the cell cycle status of each population were analyzed by flow cytometry. We found that CD24 þ population was enriched for cells at the S phase (Figure 2c ), which may lead to the chemotherapeutic resistance of cisplatin compared with CD24
À cells, because recent work has defined cancer as a cell cycle disease, and drug therapy of malignant diseases has classically relied on cytotoxic agents, most of which act in a cell cycle-specific manner or influence the cell cycle of the malignant cells (Deininger, 2004) .
Enhanced aggressiveness of CD24
þ cells in nude mice Heightened ability to form xenograft tumors is one of the defining characteristics of cancer-initiating cells. We therefore carried out tumor xenograft experiments to investigate whether smaller numbers of CD24 þ cells were capable of tumorigenesis compared with CD24 À cells, as previously shown for other CSCs (Collins et al., 2005; Li et al., 2007) . Purified CD24 þ and CD24 À cells were injected s.c. into the right and left flanks of nude mice, respectively. With injection of 5 Â 10 3 cells per mouse, CD24 þ cells were tumorigenic in two of three nude mice, with tumor latency of 73 and 89 days, respectively. In contrast, no tumor was observed when 
little worse than those of the primary tumor. We also found the expression pattern of CD24 in the xenograft demonstrated all tumor cells were strong positive staining for CD24 (Immunohistochemistry-stained section; Figure 3b ).
CD24
þ cells preferentially expressed stem cell genes In order to address whether CD24 þ cells have some other intrinsic properties conferring their stem cell-like characteristics, we examined the expression of some genes that are crucial molecules in specific signaling pathways connected with the roles of the programmes in establishing and maintaining stem cell-like characteristics. As shown in Figure 4 , CD24 þ cells expressed higher levels of Nestin, b-catenin, Bmi-1, Oct4, Oct3/4, Notch1 and Notch4 than the matched CD24 À counterpart. In contrast, similar levels of SMO and CK18 expression were observed in CD24 þ and CD24 À cells. Increasing evidence has demonstrated that E-cadherin, a negative regulator of the canonical Wnt signaling cascade, in particular of its central mediator b-catenin, has a crucial role in invasion and metastasis of numerous tumors (Schmalhofer et al., 2009) . It is interesting to note that we found CD24 þ cells expressed lower mRNA level of E-cadherin, with the expected association of b-catenin upregulation, than CD24 À cells, which may partly explain that CD24 þ cells are more tumorigenic than CD24 À cells in nude mice. Recently, a mechanism of chemoresistance has been associated with the hypothesis that CSCs could efflux anticancer agents to avoid damage induced by the drug, which was mediated by ABCG2, one member of the ABC family of transporter proteins (Patrawala et al., 2005) . In the preceding section, we described CD24 þ cells were more resistant to chemotherapeutic agent than CD24 À cells. In this study, we also assessed the ABCG2 expression. As expected, ABCG2 was higher expressed in CD24 þ than CD24
À population. The time after sorting (Day) Figure 2 Characteristics of CD24 þ and CD24 À populations in vitro. (a) Growth curve of CD24 þ and CD24 À sub-populations within 8 days after sorting. Cell proliferation was detected every day after they were plated in quadruple in a 96-well plate at 4000 cells per well using the XTT assay. Growth curves were prepared by the relative growth based on the percentage increase in absorbance of cells on a given day as compared with day 1, and the relative cell growth (%) ¼ ((average absorbance in a given day/average absorbance on day 1)À1) Â 100. (b) Differentiation of purified CD24 þ and CD24 À cells in subculture. Dot plots represent typical examples of CD24 expression. The purity of the sorted population was 496% as revealed by post-resorting analysis. After 2 weeks in culture, the purified CD24 þ population generated both CD24 þ and CD24 À cells, whereas CD24 À cells remained unchanged. (c) Representative histograms of cell cycle status of CD24 þ and CD24 À cells were displayed. CD24 þ population was enriched for cells at S phase.
Discussion
The progenitor cell origin theory of cancer suggests that only a small sub-population of cells within the tumor have stem-like properties and behave as tumor-initiating cells, which initiate not only the primary disease and but also its recurrence because of their capacity for selfrenewal and inherent chemoresistance. These tumorinitiating cells, also called CSCs, are typically identified by virtue of specific cell surface markers (Patrawala et al., 2005; Zhang et al., 2008) . Here, we would like to assert that CD24 is another new-found surface marker for ovarian CSCs after the discoveries of CD133 and CD44/CD117.
Initially, we successfully isolated a series of cancer cell clones from ovarian tumor specimens of a patient. These cell clones were different in growth rate, cell cycle distribution and expression profile of genes and proteins although they were isolated from the same patient, which indicated that ovarian cancer cells within the Representative hematoxylin and eosin staining sections of primary patient tumor and xenograft tumor. Well-formed glands with mucin were distributed (b1; Â 40) and tumor cells were basally located and bland-looking (b2; Â 200) in primary tumor. Identical mucinous adenocaricnoma was formed in the subcutaneous fat tissue and back muscle of the nude mouse (b3; Â 10); mucinous glands were found in the xenograft tumor mass (b4; Â 100); and cytologically, xenograft tumor cells were bizarre, hyperchromatic and pleomorphic (b5; Â 400). Immunohistochemistry staining of anti-CD24 antibody in xenograft tumor, with brown staining indicating the presence of specific antigen (b6; Â 400).
CD24
þ cells in ovarian cancer M-Q Gao et al tumor were organized as a hierarchy. What we should point out was that the large variability in the CD24 þ and CD133 þ populations among all clonal lines analyzed by flow cytometry did not match the data analyzed by RT-PCR, in which 16 and 15 of 20 lines appeared to express identical amounts of CD24 and CD133, respectively. Hence, we further carried out flow cytometry analysis to investigate the protein expression of CD44, which was equally expressed at mRNA level in all cell clones and found that all 20 clonal lines varied from exhibiting 34.8 to 98.4% CD44 þ cells (Supplementary Figure S2 ), which was also unparallel to the mRNA level. This phenomenon could be explained by the saturation of amplification reaction because of excessive PCR cycles (35 cycles in our RT-PCR condition) and any variability in the expression of stem cell markers would be undetectable. Thus, it was not an effective way to screen the potential ovarian CSC markers based on the RT-PCR analysis. But, at least, the different mRNA and protein expression level of CD24, CD117 and CD133, as well as varying growth rate and cell cycle distribution among all 20 clonal lines suggested that ovarian cancer cells are organized as a hierarchy.
The task we were faced with in the following step was to make sure which was the best choice for ovarian CSC marker among all the potential stem cell markers including ABCG2, CD133, CD24, CD34, CD44, CD117/c-kit, EpCAM, E-cadherin, b-catenin, SMO, Bmi-1, Nestin, Notch1, Notch4, Oct3/4, Oct4 and CK18. Instead of doing other time-consuming and laborious studies to screen a potential ovarian CSC marker, we slightly subjectively focused on CD24, CD117, CD133 and CD44 based on the fact that they were most frequently used to identify CSC in previous reports as well as their different protein expression levels in all the clonal lines. However, in view of that CD117/ CD44 and CD133 have been identified as ovarian CSC markers in previous studies (Ferrandina et al., 2008; Zhang et al., 2008; Baba et al., 2009) , we finally picked out CD24 and hypothesized it was another surface marker to identify ovarian CSCs. In addition, the correlation between the expression of CD24 in ovarian tumor tissue and poor prognosis of patients (Kristiansen et al., 2002) as well as the two-edged role of CD24 in the identification of breast and pancreatic CSCs also contributed to our final determination of CD24.
To date, based on stem cell behavior in normal epithelia, at least four criteria are established to indicate persistence of a stem cell pattern, including (a) the capacity to remain quiescent (Friel et al., 2008) , (b) generation of an amplification hierarchy (Patrawala et al., 2005) , (c) resistance to chemotherapy (Hermann et al., 2007) and (d) enhanced tumorigenicity in mice model (Li et al., 2007) . In this study, we demonstrate these properties within a sub-population of primary human ovarian cancer cells that were isolated by CD24 sorting. The experiments we described here provide a series of evidence to support that CD24 þ cells isolated from cancer cells possessed stem cell-like properties. CD24 þ cells proliferated slowly compared with CD24 À fraction and were able to self-renew and produce heterologous descendent CD24 À cells in culture, CD24 þ cells were more resistant to chemotherapeutic drug, and possessed enhanced tumorigeniticy than the matched CD24
À counterparts, as evidenced by the in vivo time to appearance of tumors in animals injected with equal numbers of CD24 À cells may be shorter in those receiving CD24 þ cells. We should note it remains possible that the nude mice injected with CD24 À fraction could develop tumors if they were monitored for a longer period. At least we can draw such a conclusion that CD24 þ cells were more tumorigenic than CD24 À cell in nude mice. In addition, the expression pattern of CD24 in the xenograft demonstrated all tumor cells were strong positive staining for CD24, which was different from the forenamed discovery that CD24 þ cells were able to differentiate into CD24 À cells in vitro within 2 weeks after sorting. The possible reason is that it needs longer time for the differentiation of CD24 þ cells during the tumor growth in vivo because cell differentiation is regulated by many factors, or CD24 þ cells produce CD24 À cells only as needed, for example, the metastasis.
The majority of ovarian cancer patients who respond to primary chemotherapy ultimately develop recurrent, usually drug-resistant, disease that is conceivably because of the ability of ovarian cancer stem cells to escape these drugs. ABCG2 transporter confers the ability to not only define a stem cell-like Hoechst 33342-excluding side populatioin but, perhaps more importantly, the drug resistance-associated efflux of many lipophilic chemotherapeutic agents (Doyle and Ross, 2003) . Here, we demonstrate that candidate human Figure 4 RT-PCR analyses of expression of stem cell genes in purified populations sorted by fluorescence-activated cell sorting against antibody of CD24. GAPDH mRNA expression was used as an internal control.
þ cells in ovarian cancer M-Q Gao et al ovarian cancer stem cells, defined as CD24 phenotype cells, were more resistant to cisplatin and expressed higher level of ABCG2 than CD24 À cells, confirming these stem cell-like characteristics as a potential mechanism for drug resistance.
Until now, whether CSCs relate to cell cycle distribution is controversial, for instance, it has been suggested that neither highly tumorigenic (CSCs) nor nontumorigenic population in the breast and the pancreatic cancer was enriched for cells at a particular stage of the cell cycle (Al-Hajj et al., 2003; Li et al., 2007) , whereas human endometrial cancer lines AN3CA-derived side population cells (CSCs) accumulated in the G1 phase of the cell cycle compared with non-side population fraction (Friel et al., 2008) . We found that CD24 þ population (CSC) was enriched for cells at the S phase compared with CD24 À population. This finding seemed inconsistent with that CD24 þ cells were slower growing than CD24
À cells confirmed in the preceding section, because it is generally believed that cells in the S-phase of cell cycle progression possess higher proliferation capacity than those in other cell cycle stages. The possible reason for this contradiction is that the loss of regulation that CD24 þ cell received within the unsorted cancer cells induced the replication of DNA in their nuclei to make a preparation for further proliferation and differentiation, nevertheless, it was insufficient for the CD24 þ cells to finish a cell cycle progression, thus leading to an increased S-phase but a slower cell cycle. In addition, recent findings also revealed that cell growth was an essential requirement for cell cycle progression, whereas the growth was independent of cell cycle position. For instance, Jaksch et al. (2008) suggested that the proliferation rate was not significantly different between CD133
þ sorted Caco2 cells with DNA content of 4N or even greater (S or G2/M portion of the cell cycle) and CD133
À sorted Caco2 cells with 2N DNA (G0/G1 portion of cell cycle) (Jaksch et al., 2008) , whereas the publication by Goranov et al. (2009) showed that cell growth was faster in cells arrested in anaphase and G1 than in other cell cycle stages.
We also found CD24 þ cells preferentially expressed stem cell genes that have an essential role in stem cell self-renewal, proliferative capacity and fate determination (Chambers and Smith, 2004; Fuchs et al., 2004) , which suggested stem cell-like characteristics of CD24 þ cells were mediated by multiple signaling pathways, especially those involved in the regulation of stem cell function and niche-stem cell interactions, for example, Wnt signaling and Notch signaling. To clear which pathway has a leading role and how to cross talk with each other, further study should be done.
We propose that CD24 might be used to detect and isolate ovarian cancer stem cells for further characterization following the previous discoveries of CD117/CD44 and CD133. Regardless of whether CD24 þ cancer cells are truly cancer stem cells or early progenitor cells, therapies targeted at CD24 may provide a new method for clinical therapeutic strategies against ovarian cancer.
Materials and methods
Cell isolation from human ovarian tumors
Tumor tissue specimens categorized as serous or mucinous (cyst) adenocarcinoma were obtained from an ovarian cancer patient during surgical procedure. The study was approved by the local ethics committee and consent was obtained from the patient. Tumor tissues were washed and cut into small pieces with scissors and then minced completely using sterile scalpel blades, followed by incubation with extracellular matrix degrading enzymes such as dispase, pronase and DNase (all Sigma, St Louis, MI, USA) for 12 h at 37 1C. At the end of incubation, cells were filtered through a 100-mm nylon mesh and washed twice with HBSS/2% FBS. To eliminate erythrocytes, dead cells and other tissue debris, cell suspensions were subjected to ficoll (1.077 g/ml) gradient centrifugation at 400 g for 15 min. The cell pellet was collected and suspended in Iscove's modified Dulbecco's medium (IMDM, Gibco BRL, Grand Island, NY, USA) containing 100 IU/ml penicillin and 100 mg/ml streptomycin (Gibco BRL), 100 mg/ml gentamicin (Gibco BRL), 2.5 mg/ml amphotericin (Gibco BRL) and 20% FBS. In the following step, cell suspension was seeded in 24-well plates and maintained in a humidified atmosphere of 95% air and 5% CO 2 at 37 1C. Tumor cells were separated from fibroblasts by stable trypsin-like enzyme (Gibco BRL) based on the observation that fibroblasts detach earlier from the flask after trypsinization. Each cell population was periodically recloned by plating single cells in medium under direct vision and expanding fresh populations from a single clone. Once isolated and recloned, each clone was examined for the expression of stem cell markers to determine potential surface markers for ovarian CSCs.
RNA extraction and RT-PCR
Ribonuucleic acid was extracted from cells using an Ultraspec-IIRNA kit (Biotecx Laboratories, Houston, TX, USA) according to the manufacturer's protocol. Complementary DNA was synthesized using 0.5-2 mg of total RNA with SuperScript III reverse transcriptase kit (Invitrogen, Carlsbad, CA, USA), and 2 ml cDNA product was amplified by RT-PCR. GAPDH was used as an internal control in all reactions. PCR products were separated on 2% agarose gel and stained with ethidium bromide. Primers, product size, and PCR conditions are listed in Supplementary Table S1 .
Flow cytometry and fluorescence-activated cell sorting Detached cells were counted and washed twice with HBSS (calcium and magnesium free) containing 2% heat-inactivated FBS (5 min at 300 g), and then resuspended in HBSS/2% FBS at concentration of 10 6 cells/90 ml. A total of 10 ml of FcR blocking reagent (Miltenyi Biotec, Auburn, CA, USA) was added and incubated at 4 1C for 10 min, after which the sample was washed once and resuspended in 100 ml of HBSS/2% FBS. Antibodies were then added and incubated for 20 min on ice in the dark. After washing twice, cells were resuspended in HBSS/ 2% FBS (2 Â 10 6 cells/ml) containing 1 mg/ml 7-AAD (Sigma). The suspension was filtered through a 70-mm nylon mesh. Samples were analyzed on a FACSCalibur flow cytometer (Becton Dickinson, San Jose, CA, USA) or sorted by EPICS ALTRA flow cytometer (Beckman Coulter, Fullerton, CA, USA). Side and forward scatter profiles were used to eliminate cell doublets. Dead cells were eliminated using 7-AAD viability dye. Antibodies of anti-CD24-phycoerythrin or fluorescein isothiocyanate, anti-CD133-phycoerythrin and anti-CD117/ c-kit-phycoerythrin were obtained from BD Pharmingen (San Diego, CA, USA).
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Cell proliferation assay
Cells were plated in quadruple in 96-well plates and cultured for an appropriate period of time. Proliferation was detected using the count cell viability assay kit (WelGENE, Seoul, Korea). Cell viability was quantified by measuring the absorbance of the samples with a VersaMax microplate reader at a wavelength of 450 nm, and nonspecific readings were eliminated by using a wavelength of 690 nm.
Chemotherapeutic sensitivity assay
To assess the chemosensitivity of sorted cells to cisplatin, cells were diluted to 2000 viable cells/100 ml IMDM with 20% FBS, seeded in quadruple to a 96-well ultra low-attachment microplate (Costar, Cambridge, MA, USA), and allowed to attach and grow for 48 h before being exposed to 0, 5, 10, 20, 40, 60, 80, 100 or 120 mmol/l cisplatin (Sigma). After treatment for 72 h, relative cell numbers were determined by count cell viability assay kit. The half maximal (50%) inhibitory concentration (IC 50 ) value of cisplatin was calculated by SPSS 11.0 as means ± s.d.
Cell cycle analysis
Flow cytometry analysis of PI-stained cells was carried out to demonstrate the progression of the cell cycle. Briefly, 2 Â 10 6 sorted cells were harvested, washed and fixed in 70% ethanol overnight at À20 1C. Before flow cytometry, cells were washed and stained with 500 ml of PI staining solution (50 mg/ml PI, 0.1% Triton X-100, 0.1 mmol/ml EDTA and 50 mg/ml RNase A). DNA content was determined with a FACScan flow cytometer and the proportion of cells in a particular phase of cell cycle was determined with ModFit LT software.
Xenograft experiment for the analyses of tumorigenicity Nude mice were purchased from Central Lab Animal (Seoul, Korea) and maintained in accordance with the institutional guidelines of Yonsei University College of Medicine. All animal studies were carried out according to approved experimental protocols. To assess tumorigenicity, purified CD24 þ and CD24 À cells (5 Â 10 3 , N ¼ 3) were suspended in 100 ml 1:1serum-free-IMDM/Matrigel (BD Biosciences, San Jose, CA, USA) followed by injection s.c. into the right and left flanks of female nude mice (5-6 weeks old). Tumor formation/growth was assayed weekly as a time course. The tumor-bearing animals were killed at the same time when tumor was large enough for subsequent experiments. Animals with no sign of tumor burden were also examined on necroscopy to confirm that there was no tumor development. Xenograft tumors were resected, fixed in formalin and paraffin sections were made for hematoxylin and eosin staining or immunohistochemistry staining.
